B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

METTL3

MOLECULAR TARGET

methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit

UniProt: Q86U44NCBI Gene: 563395 compounds

METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) is targeted by 5 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting METTL3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1meclofenamic acid3.5032
2eltrombopag2.6413
3Luteolin 5,7,3',4'-tetrahydroxy-flavone,0.691
4Quercetin0.691
5s adenosylhomocysteine0.691

About METTL3 as a Drug Target

METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 5 compounds with documented METTL3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

METTL3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.